Neuroendocrine dysfunction in PCOS: A critique of recent reviews

Clinical Medicine and Research

Volumn 6, Issue 2, 2008, Pages 47-53

  Doi, Suhail A R ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Gonadotropin releasing hormone; Hyperandrogenism; Luteinizing hormone; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTROGEN; FLUTAMIDE; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; HYDROXYPROGESTERONE; INSULIN; LEUPRORELIN; LUTEINIZING HORMONE; NAFARELIN; SEX HORMONE BINDING GLOBULIN; STEROID 17,20 LYASE; TESTOSTERONE;

ANDROGENESIS; ANOVULATION; CAUTERIZATION; DIAGNOSTIC VALUE; ENZYME DEFICIENCY; FEEDBACK SYSTEM; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYDROXYLATION; HYPERANDROGENISM; HYPOTHALAMUS; INSULIN RESISTANCE; LUTEINIZING HORMONE RELEASE; MENSTRUAL IRREGULARITY; NEUROENDOCRINE DISEASE; NONHUMAN; OBESITY; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; PULSATILE HORMONE RELEASE; REVIEW; SINGLE DRUG DOSE; THECA CELL; TREATMENT OUTCOME; BIOLOGICAL MODEL; NEUROSECRETION; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

ANDROSTENEDIONE; ESTRADIOL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPERANDROGENISM; LUTEINIZING HORMONE; MODELS, BIOLOGICAL; NEUROSECRETORY SYSTEMS; POLYCYSTIC OVARY SYNDROME;

EID: 58149148264     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2008.796     Document Type: Review

References (69)

1. Blank SK, McCartney CR, Helm KD, Marshall JC. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin Reprod Med 2007;25:352-359.
2. Blank SK, McCartney CR, Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update 2006;12:351-361.
3. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab l994;79:1158-1165.
4. Ibañez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE.. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 1996; 81:4103-4107.
5. Levrant SG, Barnes RB, Rosenfield RL. A pilot study of the human chorionic gonadotrophin test for ovarian hyperandrogenism. Hum Reprod 1997;12:1416-1420.
6. Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997;47:93-99.
7. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989; 320:559-565.
8. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;16:322-353.
9. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992;327:157-162.
10. Rosenfield RL. Is polycystic ovary syndrome a neuroendocrine or an ovarian disorder? Clin Endocrinol (Oxf) 1997; 47:423-424.
11. Sahin Y, Kelestimur F. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1993;39:151-l55.
12. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD. Serum bioactive and immunoreactive luteunizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 1991;73:811-817.
13. Imse V, Holzapfel G, Hinney B, Kuhn W, Wuttke W. Comparison of luteinizung hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. J Clin Endocrinol Metab 1992;74:1053-1061.
14. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728-3733.
15. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, Hall JE. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metal, 1997;82:2248-2256.
16. Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:265-293.
17. Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. Fertil Steril 1992;58:655-666.
18. Rosenfield RL, Barnes RB, Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994;79:1686-1692.
19. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946-957.
20. Strauss JF 3rd, Wood JR, Christenson LK, McAllister JM. Strategies to elucidate the mechanism of excessive theca cell androgen production in PCOS. Mol Cell Endocrinol 2002;186:183-188.
21. Koivunen RM, Morin-Papunen LC, Ruokonen A, Tapanainen JS, Martikainen HK. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. Hum Reprod 2001;16:2546-2551.
22. Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA. Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome. J Endocrinol Invest 2005; 28:882-892.
23. Carani C, Qin K, Simoni M, Faustuni-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91-95.
24. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 1994;78:1287-1292.
25. Kesner JS, Wilson RC, Kaufman JM, Hotchkiss J, Chen Y, Yamamoto H, Pardo RR, Knobil E. Unexpected responses of the hypothalamic gonadotropin-releasing hormone "pulse generator" to physiological estradiol inputs in the absence of the ovary. Proc Natl Acad Sci U S A 198 7;84:8745-8749.
26. Yen SS. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1980;12:177-207.
27. Patel K, Coffler MS, Dahan MH, Malcom PJ, Deutsch R, Chang RJ. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:67-74.
28. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-4052.
29. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99-102.
30. Sir T. [Do androgens modulate luteinizing hormone secretion in women?]. Rev Med Chil 1997;125:710-718.
31. Sir-Petermann T, Rabenbauer B, Wildt L. The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women. Hum Reprod 1993; 8:1807-1812.
32. Dunaif A, Longcope C, Canick J, Badger T, Crowley WF Jr. The effects of the aromatase inhibitor delta 1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease. J Clin Endocrinol Metab 1985;60:773-780.
33. Dunaif A, Scully RE, Andersen RN, Chapun DS, Crowley WF Jr. The effects of continuous androgen secretion on the hypothalamic-pituitary axis in woman: evidence from a luteinized thecoma of the ovary. J Clin Endocrinol Metab 1984;59:389-393.
34. Judd HL, Rigg LA, Anderson DC, Yen SS. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1976;43:347-355.
35. Greenblatt E, Casper RF. Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome. Am J Obstet Gynecol 1987;156:279-285.
36. Mahesh VB, Brann DW. Regulation of the preovulatory gonadotropin surge by endogenous steroids. Steroids 1998;63:616-629.
37. Hall JE, Taylor AE, Martin KA, Rivier J, Schoenfeld DA, Crowley WF Jr. Decreased release of gonadotropin-releasing hormone during the preovulatory midcycle luteunizing hormone surge in normal women. Proc Natl Acad Sci U S A 1994;91:6894-6898.
38. Smith PF, Frawley LS, Neill JD. Detection of LH release from individual pituitary cells by the reverse hemolytic plaque assay: estrogen increases the fraction of gonadotropes responding to GnRH. Endocrinology 1984;115:2484-2486.
39. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57:1320-1329.
40. Young JR, Jaffe RB. Strength-duration characteristics of estrogen effects on gonadotropin response to gonadotropun-releasing hormone in women. II. Effects of varying concentrations of estradiol. J Clin Endocrinol Metab 1976;42:432-442.
41. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf) 1994; 41:473-481.
42. Dunaif A, Mandeli J, Fluhr H, Dobrjansky A. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab 1988;66:131-139.
43. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003;88:4682-4688.
44. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-154.
45. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:241-249.
46. Sattar N, Hopkinson ZE, Greer IA. Insulin-sensitising agents in polycystic-ovary syndrome. Lancet 1998;351:305-307.
47. Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Hum Reprod 2002;17:2230-2236.
48. Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002;16:217-224.
49. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:21708-2116.
50. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999;71:323-327.
51. Buyalos RP, Geffner ME, Watanabe RM, Bergman RN, Gornbein JA, Judd HL. The influence of luteinizing hormone and insulin on sex steroids and sex hormone-binding globulin in the polycystic ovarian syndrome. Fertil Steril 1993; 60:626-633.
52. Diamond MP, Grainger DA, Laudano AJ, Starick-Zych K, DeFronzo RA. Effect of acute physiological elevations of insulin on circulating androgen levels in nonobese women. J Clin Endocrinol Metab 1991;72:883-887.
53. Doi SA, Towers PA, Scott CJ, Al-Shoumer KA. PCOS: an ovarian disorder that leads to dysregulation in the hypothalamic-pituitary-adrenal axis? Eur J Obstet Gynecol Reprod Biol 2005;118:4-16.
54. Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjö T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril 1993;59:323-331.
55. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996;81:2854-2864.
56. Grulet H, Hecart AC, Delemer B, Gross A, Sulmont V, Leutenegger M, Caron J. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clin Endocrinol (Oxf) 1993;38:621-626.
57. Dale PO, Tanbo T, Vaaler S, Abyholm I. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 1992;58:487-491.
58. Ke WX, Shun GQ, Hun SY. Different responses of insulin, C-peptide, and testosterone to an oral glucose tolerance test in two groups of women with polycystic ovarian syndrome. Acta Obstet Gynecol Scand 1996;75:166-169.
59. Banaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. Rocz Akad Med Bialymst 2003;48:131-134.
60. Toprak S, Yönem A, Cakir B, Güler S, Azal O, Ozata M, Corakçi A. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res 2001;55:65-70.
61. Tropeano G, Vuolo IP, Lucisano A, Liberale L, Barini A, Carfagna P, Caroli G, Menini E, dell'Acqua S. Gonadotropin levels in women with polycystic ovary syndrome: their relationship to body weight and insulin levels. J Endocrinol Invest 1996;19:139-145.
62. Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA. Steroidogenic alterations and adrenal androgen excess in PCOS. Steroids 2006;71:751-759.
63. Doi SA, Al-Zaid M, Towers PA, Scott CJ, Al-Shoumer KA. Irregular cycles and steroid hormones in polycystic ovary syndrome. Hum Reprod 2005;20:2402-2408.
64. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499-507.
65. Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, Johnston DG, Franks S. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 1993;39:351-355.
66. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45:623-629.
67. Barber TM, Wass JA, McCarthy ML, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels:implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66:513-517.
68. Patel K, Coffler MS, Dahan MH, Yoo RY, Lawson MA, Malcom PJ, Chang RJ. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab 2003;88:5456-5461.
69. Fulghesu AM, Cucinelli F, Pavone V, Murgia F, Guido M, Caruso A, Mancuso S, Lanzone A. Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome. Hum Reprod 1999;14:611-617.